Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEMOX in advanced hepatocellular carcinoma after sorafenib
NCT05517239Phase 2Completed
- Sponsor
- Yonsei University
- Start
- May 2015
- Primary completion
- Sep 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, oxaliplatin in hepatocellular carcinoma (HCC), sponsored by Yonsei University. Started May 2015; status: completed.
02
Drugs
gemcitabineoxaliplatin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05517239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05517239.